Colonial Trust Advisors Buys 76 Shares of Zoetis Inc. (NYSE:ZTS)

Colonial Trust Advisors grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,267 shares of the company’s stock after buying an additional 76 shares during the period. Colonial Trust Advisors’ holdings in Zoetis were worth $5,257,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ZTS. Howard Capital Management Group LLC increased its position in Zoetis by 0.8% in the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the last quarter. Principal Financial Group Inc. increased its position in Zoetis by 17.3% in the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the last quarter. MML Investors Services LLC increased its position in Zoetis by 3.2% in the third quarter. MML Investors Services LLC now owns 72,982 shares of the company’s stock worth $14,259,000 after purchasing an additional 2,276 shares during the last quarter. Geode Capital Management LLC boosted its stake in Zoetis by 1.8% during the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock worth $2,030,813,000 after buying an additional 185,364 shares during the period. Finally, Toronto Dominion Bank boosted its stake in Zoetis by 18.8% during the third quarter. Toronto Dominion Bank now owns 233,486 shares of the company’s stock worth $45,618,000 after buying an additional 37,013 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $215.90.

Zoetis Trading Up 6.5 %

Shares of NYSE:ZTS opened at $153.85 on Thursday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The firm has a market capitalization of $68.89 billion, a price-to-earnings ratio of 28.13, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business’s 50 day moving average price is $163.46 and its 200-day moving average price is $172.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.